![]() Global market research firm Canalys released the latest research report, pointing out that by the end of 2020, only 10% of every 1 billion vehicles in use worldwide are equipped with advanced driver assistance systems (ADAS). Canalys: Only 10% of every 1 billion cars in use are equipped with ADAS After this round of financing, the company will continue to rely on AR/AI technologies such as space computing, AR cloud, natural interaction and AR smart hardware to strengthen and upgrade the AR platform HiAR Space and accelerate application of their products and services in vertical industries. ![]() The new round was led by CITIC PE, with participation from Jadex Capital, Yuanhui Capital and other existing investors such as V Star Capital, Xinxi Capital, Ondice Capital, MYEG, etc. AR company HiScene completes a RMB270 million series C+ roundĪR technology company HiScene announced the completion of a RMB270 million series C+ round financing. LinkDoc plans to raise US$300 million before HK IPOĪlibaba-backed medical information platform LinkDoc Technology will start a new round of financing before Hong Kong IPO, and plans to raise US$300 million. Robovan’s design is based on Jiangling’s battery electric vehicle model, equipped with WeRide’s full-stack software and hardware solutions. WeRide launches first L4 self-driving cargo vanĬhinese autonomous driving technology developer WeRide launched its first L4-level self-driving cargo van yesterday and announced that it will work with Jiangling Motors, a major Chinese automobile manufacturer, and ZTO Express, a leading express delivery company in China, to drive mass production and the commercialization of the newly unveiled WeRide Robovan. The newly adjusted indicative price band is between ₩45,000 and ₩52,000, implying a market cap range of ₩4.57~5.28T.China Tech Digest: WeRide Launches First L4 Self-driving Cargo Van LinkDoc Plans To Raise US$300 Million Before HK IPO As a result, the bookbuilding opening is also pushed back to July 5. The total number of offerings is 12,442,200 shares, up to 75% of which will be allocated to institutional investors. SD Biosensor submitted a correction to its securities declaration on June 11 and postponed its IPO to July. This is probably thanks to the surge in the share price of Seegene, the only valuation peer, in the aftermath of the COVID-19 mutant virus. Investor sentiment toward SD Biosensor’s IPO appears to be changing. We think the company’s fairly valued for its fundamentals. In this note, we provide an update for the book building. We also compared the company’s key financial metrics with other leading listed ICL. The management’s experience is also decent. We think the company has a decent line-up of investors but there is still a lack of international healthcare investors. We think the company can continue to grow the existing pie of hematological tests for which the public hospitals do not want to invest in the test equipment and processes but it will be challenging for the company to expand the business into the area where public hospitals are willing to invest in. The company is relatively weak in other areas such as oncology and maternity related businesses. The company has a strong footprint in the hematology test segment with the majority of its revenue is derived from the hematological tests, particularly for lymphoma and myeloma-related diseases. ![]() ![]() In our previous note, we discussed Kindstar’s business segment. The company launched book building to raise up to USD 285m via a Hong Kong listing. Kindstar is a leading esoteric test service provider in China. In a follow-up insight, we will be discussing the company’s margins. In this insight, we discuss in detail Medlive’s business model, segments, industry prospects and the company’s top line growth. Medlive is well positioned to benefit from growing demand for digital healthcare marketing and digital healthcare education and information services in China driven by increased health awareness, technological advancements, prevalence of chronic conditions and favourable government policies. The company is backed by the Japanese healthcare and medical-related services platform M3. Medlive has filed for an IPO to list its shares on the Hong Kong Stock Exchange and plans to raise proceeds of about US$500m. The company generates revenues primarily through offering digital marketing services to pharmaceuticals and healthcare companies, research and education/learning content to physicians and internet hospital services to patients. Medlive Technology (MLT HK) is the largest online professional physician platform in China based on registered physician users in 2020 (Source: Frost & Sullivan).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |